What's Happening?
Invivoscribe, a biotechnology company specializing in precision diagnostics, has announced the launch of the PrepQuant System, an integrated sample preparation platform. Developed in collaboration with
Hitachi High-Tech Corporation, the system combines nucleic acid extraction, concentration, and quantification into a single automated instrument. This innovation aims to standardize sample preparation and simplify pre-analytical workflows, reducing costs and eliminating inconsistencies in molecular testing. The PrepQuant System is assay agnostic, generating highly concentrated genomic DNA and cell-free DNA yields for next-generation sequencing, qPCR, and digital PCR assays.
Why It's Important?
The PrepQuant System represents a significant advancement in precision medicine, where the reliability of measurable residual disease and liquid biopsy results depend heavily on the quality and consistency of the starting material. By integrating multiple steps into one platform, the system reduces laboratory operating costs, sample variability, and lab bench space, while optimizing test results. This is crucial in the era of precision medicine, as it ensures consistent, high-quality test results, which are vital for accurate diagnosis and treatment planning.
What's Next?
Invivoscribe plans to unveil the PrepQuant System at the American Association for Cancer Research Annual Meeting in San Diego. The company is issuing quotes and anticipates first commercial shipments in North America by August 2026, with European availability planned for January 2027. Invivoscribe also expects to release new kits by the end of 2026, further expanding the system's menu and versatility across molecular testing.
